Want to see IN:HESTERBIO full AI Analyst Report?
HESTERBIO Stock Chart & Stats
₹1605.75
-₹5.75(-0.24%)
At close: 4:00 PM EST
₹1605.75
-₹5.75(-0.24%)
Day’s Range― - ―
52-Week Range₹1,250.95 - ₹2,669.00
Previous CloseN/A
Volume2.45K
Average Volume (3M)264.00
Market Cap
₹19.05B
Enterprise Value₹12.70B
Total Cash (Recent Filing)₹65.38M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)13.9
Beta0.60
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)160.60
Shares Outstanding8,506,865
10 Day Avg. Volume151
30 Day Avg. Volume264
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue ExpansionSteady multi-year revenue expansion, followed by stronger growth in 2026, indicates continued demand for Hester Biosciences’ animal healthcare products. Sustained top-line progress can support operating scale, broaden market reach, and provide a foundation for future investment in vaccines and related products.
Profitability ReboundThe return to a roughly 16.7% net margin and improved operating profitability strengthens the company’s earnings base after weaker periods. If maintained, healthier margins can improve internal funding capacity, support product development and distribution, and increase resilience across animal-health demand cycles.
Lower Leverage And Positive Free Cash FlowMeaningful deleveraging alongside several years of positive free cash flow improves financial flexibility and reduces balance-sheet pressure. Lower leverage can leave more capacity for operating investment and product expansion, while internally generated cash provides a stronger base for meeting obligations and funding growth.
Bears Say
Margin VolatilityLarge historical swings in gross margin and net income make the company’s earnings profile less predictable. Persistent variability can complicate planning, reduce confidence that recent profitability will hold, and limit the reliability of earnings as a source of funding for sustained expansion.
Weak Debt CoverageOperating cash flow coverage below 1x indicates that recurring cash generation has not been sufficient to cover debt comfortably. This can constrain capital allocation, increase sensitivity to any profitability slowdown, and leave less flexibility for investment or repayment if cash conversion weakens.
Cash-Flow Execution VolatilityThe shift from deeply negative free cash flow in 2022–2023 to positive generation in later years shows improvement, but also highlights uneven cash conversion and reinvestment execution. Such variability can make funding needs harder to forecast and may pressure the balance sheet during weaker operating periods.
Hester Biosciences Limited News
HESTERBIO FAQ
What was Hester Biosciences Limited’s price range in the past 12 months?
Hester Biosciences Limited lowest stock price was ₹1250.95 and its highest was ₹2669.00 in the past 12 months.
What is Hester Biosciences Limited’s market cap?
Hester Biosciences Limited’s market cap is ₹19.05B.
When is Hester Biosciences Limited’s upcoming earnings report date?
Hester Biosciences Limited’s upcoming earnings report date is Oct 29, 2026 which is in 10 days.
How were Hester Biosciences Limited’s earnings last quarter?
Hester Biosciences Limited released its earnings results on Jul 30, 2026. The company reported ₹114.003 earnings per share for the quarter.
Is Hester Biosciences Limited overvalued?
According to Wall Street analysts Hester Biosciences Limited’s price is currently Overvalued.
Does Hester Biosciences Limited pay dividends?
Hester Biosciences Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 0.49%. See more information on Hester Biosciences Limited dividends here
What is Hester Biosciences Limited’s EPS estimate?
Hester Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hester Biosciences Limited have?
Hester Biosciences Limited has 8,506,865 shares outstanding.
What happened to Hester Biosciences Limited’s price movement after its last earnings report?
Hester Biosciences Limited reported an EPS of ₹114.003 in its last earnings report. Following the earnings report the stock price went down -1.295%.
Which hedge fund is a major shareholder of Hester Biosciences Limited?
Currently, no hedge funds are holding shares in IN:HESTERBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hester Biosciences Limited
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.
Technical Analysis
Sigachi Industries Limited
―
Venus Remedies Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―
Gujarat Themis Biosyn Ltd
―







